No high-conviction trade or specific price target is provided; treat the discussion as a list of risks and themes, not a buy or sell signal. Monitor Bayer (BAYRY; BAYN) for court decisions and regulatory reviews that could affect glyphosate-related liabilities. Watch for actual rule changes on food labeling and school meals that could affect PepsiCo (PEP), Coca-Cola (KO), and Mondelez (MDLZ), and verify developments through company disclosures and primary sources. Moderna (MRNA) and Pfizer (PFE) warrant attention to verified clinical-trial and regulatory updates; the claims in the discussion alone are not a basis for trading.

Bayer AG (BAYRY; BAYN)

• Guest Calley Means identified Bayer as the maker of glyphosate-based products and alleged that the company and pesticide-industry lobbyists pushed for legal protections from lawsuits. He said lawsuits over glyphosate had been settled for billions of dollars and described government review of the chemical as overdue.
• Means also claimed the Trump administration supported a Supreme Court case related to pesticide-maker liability protection. These are the guest’s claims, not independently verified findings in this analysis.
• The discussion framed glyphosate as central to U.S. farming, while noting that farmers’ reliance on it could make an immediate phaseout difficult.

Takeaways

• For investors, the discussion highlights legal, regulatory, and reputational risks for Bayer, as well as potential financial implications if liability protections change.
• Track court decisions, pesticide reviews, and any changes to agricultural practices. The transcript gives no price target or investment recommendation.

PepsiCo (PEP)

• Means alleged that PepsiCo was among the companies whose money or influence affected policy discussions, including proposals concerning school meals and a definition of ultra-processed food.
• He said major junk-food companies’ stocks rose 8% on the day he resigned. He did not identify the companies or provide details showing what drove that move.

Takeaways

• The discussion points to possible policy and reputational risks for food and beverage companies if school-meal rules or food-labeling standards change.
• The reported 8% move is an observation from the guest, not evidence of a lasting trend or a company-specific catalyst.

The Coca-Cola Company (KO)

• Coca-Cola was mentioned in the context of lobbying and proposed changes to food-assistance rules. Means argued that public funds should not support soda purchases through SNAP.
• He also described efforts to define ultra-processed food, saying that greater transparency could affect food-company sales. He did not provide a company-specific estimate of the impact on Coca-Cola.

Takeaways

• Potential policy changes to food assistance, school meals, and product definitions could create regulatory and consumer-perception risks for beverage companies.
• The transcript offers no company-specific financial analysis or price target.

Mondelez International (MDLZ)

• Means described meeting with a Mondelez lobbyist representing Oreo and said the lobbyist opposed an ultra-processed-food definition because it could hurt the company’s business. This is the guest’s account of the exchange.

Takeaways

• The discussion suggests that new food definitions or labeling requirements could become a policy risk for packaged-food companies.
• Monitor actual rulemaking and company disclosures rather than treating the guest’s account as evidence of a specific earnings impact.

Eli Lilly (LLY)

• Means said CEO Dave Ricks was frequently in Washington and described a dinner where Ricks heard concerns about pharmaceutical incentives. The transcript does not identify a specific policy decision or allegation of misconduct by Lilly.

Takeaways

• The relevant investment theme is the pharmaceutical industry’s exposure to government policy and lobbying scrutiny, not a company-specific call on Lilly.
• No price target, timeline, or specific investment recommendation was discussed.

Moderna (MRNA)

• Means discussed Moderna’s mRNA flu-vaccine application. He alleged that its trial used an outdated comparison vaccine, reported an absolute risk reduction of 0.8%, and included deaths in the trial group. He said the FDA initially sought further study before the vaccine was later approved.
• These are serious claims made by the guest; the transcript does not provide enough information to assess the underlying trial data or establish the claims independently.
• Means also mentioned a Moderna joint venture involving Blackstone and said hundreds of millions of dollars had been invested in it.

Takeaways

• The discussion underscores clinical-trial, regulatory, and public-confidence risks for vaccine developers.
• Investors should evaluate the underlying trial results and regulatory record directly; the transcript itself is not a basis for judging the vaccine’s safety or commercial prospects.

Pfizer (PFE)

• Means said Pfizer had agreed to conduct a further COVID-vaccine study as a condition of approval, then alleged that the requirement was later dropped. He suggested the company had pushed to avoid the study; the transcript does not independently establish that motive.
• Pfizer was also listed among the companies that Means said had industry relationships with political consultant Tony Fabrizio.

Takeaways

• The discussion raises potential regulatory, political, and public-trust risks for Pfizer, but offers no new company financial data or investment recommendation.
• Verify the regulatory history and any study requirements through primary sources before drawing conclusions.

Merck & Co. (MRK)

• Merck was mentioned because Means said a senior vaccine official had previously led vaccines at the company. The transcript did not allege specific conduct by Merck or present a company-level investment thesis.

Takeaways

• This was background about an official’s prior experience, not a substantive discussion of Merck’s business or stock.
• No actionable company-specific investment insight was provided.

Altria Group (MO) and British American Tobacco (BTI)

• Means said major tobacco companies, including Altria and British American Tobacco’s U.S. subsidiary R.J. Reynolds, were shifting toward vaping and lobbying around the sector.
• He cited an estimated $8 billion for the U.S. vaping market in 2026, but the transcript does not establish the estimate’s source or methodology.
• The policy debate focused on fruit-flavored vapes and youth access. Means alleged that officials prioritized a more permissive path for flavored products; this was his account of the issue.

Takeaways

• Vaping may offer tobacco companies a growth area, but the discussion also highlights substantial regulatory and youth-health risks, particularly around flavored products.
• Treat the market-size figure as an estimate, not a verified forecast. The transcript gives no stock-specific valuation or recommendation.

Kratom Products and Companies

• Means characterized kratom-derived products, especially concentrated 7-OH products, as opioid-like and said they were being sold through gas stations and other retailers. He cited an estimated $3 billion industry and described lobbying over permitted concentration levels.
• Joe Rogan recounted personal experiences with kratom and described reports of addiction. Those anecdotes do not establish the prevalence of harm or the outlook for the industry.

Takeaways

• The discussion points to a potentially significant regulatory and product-safety risk for businesses selling concentrated kratom products.
• No specific publicly traded company was named, and the transcript provides no basis for identifying a particular investment opportunity.

Health Insurers (No Companies Named)

• Means argued that the Affordable Care Act benefited insurers and claimed insurer stocks had risen 15-fold since its passage. He also claimed premiums had increased by 1.5 times. The transcript does not provide a list of insurers, a calculation method, or a time period for the stock comparison.

Takeaways

• The broader theme is policy exposure: healthcare legislation and regulation can affect insurers’ pricing and business models.
• The historical figures are the guest’s claims and should not be treated as a sector-wide performance measure without independent verification.

Psychedelic Treatments and Research

• Means and Rogan discussed potential federal support for research and faster review of psychedelic treatments, including ibogaine, for addiction and veterans’ health.
• Means said the initiative had faced institutional delays but was moving forward after presidential involvement. No company, approval timeline, or specific investment was named.

Takeaways

• The discussion identifies a speculative opportunity theme in psychedelic-drug research, alongside substantial regulatory and development uncertainty.
• No specific investment recommendation or timeline was given.

Regenerative Agriculture

• The conversation described regenerative farming as an alternative approach that could reduce reliance on some industrial farming practices. Means said the administration had shifted several billion dollars at the USDA, but did not specify the programs or recipients.
• He argued for incentives to support regenerative farming rather than relying solely on restrictions.

Takeaways

• Regenerative agriculture is a potential long-term investment theme, but the transcript names no public companies or specific investable vehicle.
• Funding, adoption, and policy support would be important to verify before assessing the opportunity.

DraftKings (DKNG)

• DraftKings appeared in a sponsored advertisement promoting its sports-betting app, NBA content, and customer bonuses. The podcast discussion did not analyze the company’s business or stock.

Takeaways

• This was promotional content, not an investment thesis. No price target, valuation view, or company-specific risk analysis was provided.